Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Non-Small Cell Lung Cancer
A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)
This multicenter, retrospective and prospective observational, cohort study will examine the effect of second-line Tarceva treatment on long response in non-small cell lung cancer (NSCLC) participants with wild type or unknown…
- Trial name
- NCT02133508
- Where
- 39 sites in Italy
- Volunteers
- 172 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects…
- Trial name
- ATLAS (NCT04966676)
- Testing
- cfDNA blood test, Nivolumab, Ipilimumab
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- University Health Network, Toronto
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Carcinoma, Non-Small-Cell Lung Cancer
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
- Conditions
- Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
- Trial name
- SELECT-2 (NCT04401059)
- Testing
- Elemene plus first or third generation EGFR-TKIs, First or third generation EGFR-TKIs
- Where
- 7 sites in China
- Volunteers
- 744 people
- Sponsor
- Tian Xie
Non Small Cell Lung Cancer
State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients
Compared to conventional radiotherapy with photons (CRT), particle therapy (PT) has the potential to inflict maximum damage on tumors with minimum collateral damage to neighboring healthy tissue.
- Trial name
- Lung stage I (NCT02038413)
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht Radiation Oncology
Non-Small Cell Lung Cancer
Intelligent Pulmonary Rehabilitation After Lung Cancer Surgery
This study will compare an intelligent pulmonary function exercise device with usual care and natural recovery in patients recovering from lung cancer surgery.
- Trial name
- NCT07631520
- Testing
- Intelligent Pulmonary Function Exercise Device, Usual Care and Natural Recovery
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared…
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV
- Trial name
- NCT05429320
- Testing
- Local ablative therapy, Blood collection to assess for ctDNA
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers
Evaluate chemotherapy related tumor markers on non small cell lung cancer by fluorescent in situ hybridization and immunohistochemistry, targets to be studied include EGFR, c-MET, topoisomerase II, p53, topoisomerase I…
- Trial name
- NCT01141686
- Volunteers
- 90 people
- Sponsor
- Taipei Medical University WanFang Hospital
Non-Small Cell Carcinoma of Lung, Locally Advanced
Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC
This is a prospective, single-arm phase II clinical study enrolling patients with locally advanced unresectable non-small cell lung cancer.
- Trial name
- NCT07882940
- Testing
- Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Lung Cancer
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come…
- Trial name
- NCT02869789
- Testing
- Nivolumab in combination with Ipilimumab
- Where
- 136 sites in United States, Argentina and 19 more
- Volunteers
- 1,041 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that…
- Trial name
- NSCLC (NCT06928389)
- Testing
- Ivonescimab, docetaxel
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Akeso
Non-Small-Cell Lung Cancer
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03728374
- Testing
- Anlotinib
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Non-small Cell Lung Cancer
Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit
An interventional, prospective study. It is estimated that up to 800 patient tissue samples (from approximately 650 patients enrolled at approximately 300 clinical trial sites), will be obtained as part of enrolment into Phase 3…
- Trial name
- NCT05347797
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 495 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Non-small Cell Lung Cancer
Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy
In this prospective study, the investigators will evaluate and compare the usefulness of functional and volumetric informations obtained by 18F-FDG PET and MRI before and after the palliative chemotherapy with the aim of…
- Trial name
- NCT01482182
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Samsung Medical Center
Non-Small Cell Lung Cancer
A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer
This is a Phase II, single-arm study in patients with stage IIIB (with malignant pleural effusion) and IV NSCLC who have been previously treated with a platinum-based doublet. Each cycle will be 21 days.
- Trial name
- NCT00251446
- Testing
- Vinflunine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Veeda Oncology
Cancer, Breast Cancer
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy…
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML)
- Trial name
- NCT02391480
- Testing
- ABBV-075, Venetoclax
- Where
- 10 sites in United States
- Volunteers
- 128 people
- Sponsor
- AbbVie
Lung Cancer
Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells.
- Trial name
- NCT01134861
- Testing
- cisplatin, Etoposide, Vinblastine
- Volunteers
- 610 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
This 2 arm study will compare the efficacy and safety of Tarceva plus Avastin, and chemotherapy plus Avastin, in the first-line treatment of patients with advanced non-small cell lung cancer.
- Trial name
- NCT00531960
- Testing
- Erlotinib, Bevacizumab, Standard platinum-based chemotherapy
- Where
- 57 sites in Australia, Belgium and 11 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0 limited-stage SCLC
- Trial name
- Neoadjuvant (NCT06562920)
- Testing
- adebrelimab and chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Non Small Cell Lung Cancer
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
This is a phase II, non-comparative, randomized study assessing combination of Tedopi with docetaxel or with nivolumab in NSCLC patients failing after first- line chemoimmunotherapy.
- Trial name
- COMBI-TED (NCT04884282)
- Testing
- Tedopi, Nivolumab, Docetaxel
- Where
- 23 sites in France, Italy and 1 more
- Volunteers
- 105 people
- Sponsor
- Fondazione Ricerca Traslazionale
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.